Radiation Radiology Radiopharmaceuticals 
AuntMinnie
MAY 8, 2024
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. Extravasations Extravasations, in particular, are of interest to the U.S.
AuntMinnie
JULY 12, 2024
Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI. Theranostics offers hospital radiology departments the opportunity to keep more reimbursement dollars in the department, Beyder explained. The bottom line?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
FEBRUARY 26, 2025
Additionally, modalities like MRI, CT, bone scans, and PET-CT are significant contributors to greenhouse gas emissions, with radiology accounting for approximately 1% of global healthcare-related emissions. The analysis might help to establish a model for balancing clinical and environmental priorities in radiology departments globally.
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
AuntMinnie
MARCH 7, 2024
In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.
AuntMinnie
OCTOBER 25, 2024
Who made it to the final round in the 2024 edition of the Minnies, AuntMinnie.com 's event recognizing excellence in radiology? Most Influential Radiology Researcher Erik Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik Middlebrooks, MD. Most Effective Radiology Educator Francis Deng, MD, Johns Hopkins Medicine Francis Deng, MD.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Expert insights. Personalized for you.
189 
Let's personalize your content